T. Rowe Price Associates
AVNR

T. Rowe Price Associates’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

T. Rowe Price Associates’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-23,465,722
Closed -$398M – 2620
2014
Q4 		$398M Sell
23,465,722
-4,581,500
-16% -$64.5M 0.08% 279
2014
Q3 		$334M Buy
28,047,222
+2,491,100
+10% +$17M 0.07% 306
2014
Q2 		$144M Sell
25,556,122
-97,620
-0.4% -$450K 0.03% 525
2014
Q1 		$94.1M Buy
25,653,742
+842,803
+3% +$3.21M 0.02% 651
2013
Q4 		$83.4M Buy
24,810,939
+3,426,128
+16% +$14.1M 0.02% 661
2013
Q3 		$90.7M Sell
21,384,811
-337,900
-2% -$1.6M 0.02% 619
2013
Q2 		$99.9M Buy
+21,722,711
New +$74.7M 0.03% 571

T. Rowe Price Associates's AVNR Position: Q1 2015 in Review

T. Rowe Price Associates sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 23,465,722 shares — an estimated $398M sold.

T. Rowe Price Associates first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $398M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • T. Rowe Price Associates reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • T. Rowe Price Associates sold 23,465,722 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $398M.
  • T. Rowe Price Associates first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • T. Rowe Price Associates's AVANIR PHARMACEUTICALS, INC CL A position peaked at $398M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.